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Abstract
Background: There has been a rising incidence of invasive aspergillosis (IA) in critically ill patients, even in the
absence of an apparent predisposing immunodeficiency. The diagnosis of IA is difficult because clinical signs are
not sensitive and specific, and serum galactomannan has relatively low sensitivity in this group of patients.
Therefore, more prompt and accurate disease markers for early diagnosis are needed. To establish disease markers
demands a thorough knowledge of fungal antigens which may be detected in the serum or other body fluids of
patients. Herein we report novel immunodominant antigens identified from extracellular proteins of Aspergillus
fumigatus.
Results: Extracellular proteins of A. fumigatus were separated by two-dimensional electrophoresis (2-DE) and
probed with the sera from critically ill patients with proven IA. The immunoreactive protein spots were identified
by MALDI-TOF mass spectrometry (MALDI-TOF -MS). Forty spots from 2DE gels were detected and 17 different
proteins were identified as immunogenic in humans. Function annotation revealed that most of these proteins
were metabolic enzymes involved in carbohydrate, fatty acid, amino acid, and energy metabolism. One of the
proteins, thioredoxin reductase GliT (TR), which showed the best immunoactivity, was analyzed further for secretory
signals, protein localization, and homology. The results indicated that TR is a secretory protein with a signal
sequence exhibiting a high probability for secretion. Furthermore, TR did not match any human proteins, and had
low homology with most other fungi. The recombinant TR was recognized by the sera of all proven IA patients
with different underlying diseases in this study.
Conclusions: The immunoreactive proteins identified in this study may be helpful for the diagnosis of IA in
critically ill patients. Our results indicate that TR and other immunodominant antigens have potential as biomarkers
for the serologic diagnosis of invasive aspergillosis.
Background
In recent decades, invasive aspergillosis (IA) has emerged
as an important cause of morbidity and mortality in
patients with prolonged neutropenia. However, several
reports have recently described a rising incidence of IA
in critically ill patients, even in the absence of an appar-
ent predisposing immunodeficiency [1-6]. The incidence
of IA in critically ill patients ranges from 0.3% to 5.8%
[2,3,6], and carries an overall mortality rate > 80%, with
an attributable mortality of approximately 20% [4,5]. Cri-
tically ill patients are prone to develop immunologic
derangement, which renders them more vulnerable for
Aspergillus infections. The risk factors for IA include
chronic obstructive pulmonary disease (COPD) and
other chronic lung diseases [1-4,7,8], prolonged use of
steroids [2,9], advanced liver disease [2-4,10], chronic
renal replacement therapy [11,12], near-drowning
[4,13-15], and diabetes mellitus [2,3,9].
The diagnosis of such IA is difficult because signs and
symptoms are non-specific. The conventional diagnostic
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methods, such as tissue examination and microbial culti-
vation, may lack sensitivity in the first stages of infection
in critically ill patients. As a result, the diagnosis of IA is
often established after a long delay or following autopsy.
Currently, the best-characterized circulating marker
used in the diagnosis of IA is galactomannan (GM),
which is present in the cell walls of most Aspergillus
species. The commercial Platelia Aspergillus assay
(BioRad™, Marnes-La-Coquette, France) has been
included in the EORTC/MSG criteria for probable IA.
However, a recent meta-analysis indicated that GM test-
ing is more useful in patients with prolonged neutrope-
nia (sensitivity, 72%-82%) than in non-neutropenic,
critically ill patients (sensitivity, 40%-55%) [16]. Further
studies suggested that the host immune status may
influence GM release. It appears that GM production is
proportional to the fungal load in tissues [17]. Although
neutropenic patients and non-neutropenic, critically ill
patients are susceptible to IA, the pathology of the dis-
ease is quite different in these two groups of patients. In
neutropenic patients and animal models, IA is charac-
terized by thrombosis and hemorrhage from rapid and
extensive hyphal growth [18]. However, in non-neutro-
penic, critically ill patients and animal models, IA is
characterized by limited angioinvasion, tissue necrosis,
and excessive inflammation [18,19]. The limited angioin-
vasion and low fungal load result in a low level of GM
released by the fungus. The use of the GM assay for the
diagnosis of IA in non-neutropenic patients is very lim-
ited. Therefore, more prompt and accurate disease mar-
kers for early diagnosis are needed, which requires a
thorough knowledge of fungal antigens detected in the
serum or other body fluids of infected patients.
A. fumigatus is the most common opportunistic patho-
gen that causes life-threatening IA in human beings. The
ability of A. fumigatus to acquire and process growth sub-
strates from its host is dependent on factors released from
the fungi. The extracellular proteins of A. fumigatus,
which are released during the germination of conidia and
growth of hyphae, consist of secreted enzymes, toxins, and
other secondary metabolites which are pathogenic and
responsible for invasion of the structural barrier of the
host [20]. Studies on the extracellular proteins of A. fumi-
gatus and their immunogenic potential are therefore
important for further understanding the pathogenesis of
A. fumigatus and targets for the immunodiagnosis of the
diseases. It is not surprising that some of the proteins may
be major elicitors of specific immune responses, which
could be brought into play to establish prognosis and
develop new diagnostic procedures for IA.
We have recently observed that high levels of antibody
against extracellular proteins of A. fumigatus are often
present in the sera of critically ill patients with proven
IA. This finding prompted us to discover the potential
novel biomarkers for the diagnosis of IA in such patients.
The investigation of specific antigens is strongly sup-
ported by the combination of immunoproteomics and
bioinformatics. The completion of the genomes of
A. fumigatus [21] and other Aspergillus species [22-25]
makes it possible to identify the antigens of Aspergillus
species on a global scale. In this study we searched for
the immunodominant antigens from the crude culture
filtrate using an immunoproteomic approach. As a result,
a total of 17 immunodominant antigens were identified.
One of the antigens, thioredoxin reductase GliT (TR),
which showed the best immunoactivity, was cloned and
expressed in Escherichia coli. Our results indicate that
this protein could be useful for the early diagnosis of IA.
Results
Characterization of the patients
Six patients with proven IA, and different underlying dis-
eases and expressing high levels of anti-Aspergillus antibo-
dies were selected for the immunoproteomic analysis. The
details of the characteristics of the six patients with proven
IA are listed in Table 1, histopathological results are given
in Additional file 1 and the Western blots are shown in
Figure 1. Multiple bands of immunogenic proteins were
observed in each case, but not in the control sera. The
enzyme-linked immunosorbent assay (ELISA) values of
the patients with proven IA and the controls ranged from
1.105 to 2.561 and 0.114 to 0.362, respectively.
Identified immunoreactive proteins
The 2-DE and Western blot analyses of the filtrate pro-
teins are shown in Figure 2. A total of 40 distinct immu-
noreactive spots were identified. The 39 successfully
identified spots corresponded to 17 individual proteins.
The sequence coverage ranged from 18%-70%, and the
MASCOT scores were from 68 to 258. The identified
proteins with molecular weights, isoelectric points, Mas-
cot scores, and sequence coverage are listed in Table 2
(MS data of all immunoreactive spots identified are
shown in Additional file 2). Several proteins occurred in
multiple spots. Post-translational modifications are a
likely explanation, resulting in altered molecular masses
and/or isoelectric points. All 17 proteins are shown as a
protein spot on the 2-DE gel and a corresponding immu-
nogenic spot on the matching film. Of 17 identified pro-
teins, 14 were matched with A. fumigatus (Af 293), and 3
showed homology to proteins from another Aspergillus
species. Most of these proteins are metabolic enzymes
that are involved in carbohydrate, fatty acid, amino acid,
and energy metabolism. Seven of these proteins have
been reported as antigens of Aspergillus and other fungi,
and others have not been described as antigens before,
such as fumarylacetoacetate hydrolase FahA, aldehyde
dehydrogenase AldA, aromatic aminotransferase Aro8,
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G-protein comlpex beta subunit CpcB, actin cytoskeleton
protein (VIP1), phytanoyl-CoA dioxygenase family, urate
oxydase UaZ, 3-hydroxybutyryl-CoA dehydrogenase, pro-
teasome component Pre8, putative and hypothetical pro-
tein. One protein of interest, which showed the best
immunoreactivity, was identified as TR.
Bioinformatics analysis of TR
TR was predicted as a secretory protein with the presence
of signal sequences with good predictive value (signalP
probability, 0.808). The protein localization of TR was pre-
dicted using WoLF PSORT, and the result also indicated
that this protein might be an extracellular protein (Query
Protein WoLFPSORT prediction: extr, 12.0; cyto, 6.5;
cyto_nucl, 4.0; mito, 3.0; pero, 2.0). This protein was
BLAST-searched for sequence homology with human pro-
teins and other fungi using the BLAST program (http://
www.ncbi.nlm.nih.gov/BLASTp). The results indicated
that TR of A. fumigatus had no matches with human pro-
teins. Furthermore, TR of A. fumigatus had low homology
with other fungi, such as Candida albicans (25%), C. tropi-
calis (25%), C. glabrata (24%), C. guilliermondii (27%),
C. dubliniensis (23%), Saccharomyces cerevisiae (24%),
Cryptococcus neoformans (28%), and Penicillium marneffei
(27%). This protein was also BLAST-searched for
sequence homology with all protein databases using the
Table 1 Clinical characteristics of proven IA patients
Patient Age
(years)









1 30 Female systemic lupus
eythematosus,
lupus nephritis




2 39 Male Shock, previously healthy None lung Alive BAL,
A. fumigatus
Transbronchial biopsy




4 44 Male near-drowning None lung Alive BAL,
A. fumigatus
Transbronchial biopsy
5 56 Female Chronic obstructive
pulmonary disease
Methylprednisolone lung Alive BAL,
A. fumigatus
Transbronchial biopsy





Abbreviations: BAL = bronchoalveolar lavage
Figure 1 Western blot analysis of A. fumigatus extracellular proteins and sera of proven IA patients. Filtrate proteins (10 μg) of A.
fumigatus during growth in YEPG medium at 37°C for 14 days were separated by SDS-PAGE and probed with sera from 6 patients with proven
IA and control patients. Lane M, molecular weight marker; lanes 1-6, shows Western blot with sera from each of 6 proven IA patients; lane 7,
shows Western blot with pooled sera of control patients.
Shi et al. BMC Microbiology 2012, 12:11
http://www.biomedcentral.com/1471-2180/12/11
Page 3 of 9
Uniprot program (http://www.uniprot.org). The results
indicated that TR of A. fumigatus has < 55% homology
with all proteins in the databases, excluding pyridine
nucleotide-disulphide oxidoreductase of A. fischeri (identi-
tiy, 94%) and the putative uncharacterized protein of
A. terreus (identitity, 80%). TR of A. fumigatus also had
low homology with most other Aspergillus species, such
as A. oryzae (55%), A. flavus (54%), A. nidulans (50%),
A. clavatus (47%), and A. niger (41%), as shown in Addi-
tional file 3.
Expression and antigenicity of TR recombinant protein
After induction by isopropyl-b-D-thiogalactoside (IPTG),
the recombinant 6-His-tagged TR was expressed, and a
novel protein band corresponding to 36 kDa was detected
by SDS-PAGE (Figure 3A). Most of the recombinant pro-
teins were soluble. After purification using a TALON
metal affinity resin, the protein purity was approximately
91%. Protein identity was unambiguously confirmed by
MALDI-TOF MS, whereas following tryptic digestion pro-
teins were identified yielding 37% sequence coverage (the
MS spectra are shown in Additional file 4). Western blot
showed that the recombinant proteins could be recognized
by the sera from all six patients with proven IA (Figure 3B).
Discussion
Aspergillus fumigatus is known as the most common cause
of IA in humans. The extracellular proteins of A. fumiga-
tus, which functions in enabling the fungi to adhere to
host tissues and take up nutrients from the hosts, play an
important role in the interaction between fungi and hosts.
The extracellular location of these proteins enables the
proteins to interact easily with the host immune system.
Accordingly, studies on the immunogenic nature of these
extracellular proteins are of particular importance to
understand the pathogenesis of A. fumigatus. The immu-
nogenic proteins may represent candidate markers for the
diagnosis of IA. In fact, preparations of A. fumigatus extra-
cellular proteins have been used to detect antibodies in the
sera of human patients or experimentally infected animals,
and culture filtrates have also been used to raise polyclonal
antibodies to detect A. fumigatus antigens in the sera or
urine of patients or experimentally infected rats [26,27].
Our group has previously observed that high titers of anti-
bodies against extracellular proteins of A. fumigatus are
often present in the sera of critically ill IA patients
(unpublished data). However, knowledge of the extracellu-
lar proteins of A. fumigatus and the corresponding antibo-
dies is limited. To investigate the immunodominant
antigens, the extracellular proteins at different intervals
were extracted from 4 media (Aspergillus minimal med-
ium, YEPG, Czapek-Dox medium, and RPMI-1640), then
probed with sera of IA patients. The results indicated that
the protein yield reached a maximum at 14 days, and the
YEPG culture supernatant contained the maximum num-
ber of proteins reacting with the sera in comparison to
other media (unpublished data). Thus, the 14-day YEPG
filtrate proteins were used in a subsequent study.
In the present study, the immunodominant proteins
from the culture filtrate of A. fumigatus were detected
using an immunoproteomic approach. The immunoreac-
tive protein spots showing a significantly different pattern
of recognition in sera from IA patients when compared
with specimens from controls were characterized by MS.
Of 17 identified proteins, 7 have been reported as antigens
of Aspergillus and/or other fungi. For example, DppV, TR,
FAD-dependant oxygenase, pectate lyase A, aspartyl ami-
nopeptidase, and NAD-dependent malate dehydrogenase
are already known as antigens or allergens of Aspergillus
[28-31]. Fructose-bisphosphate aldolase was identified as
Figure 2 2-DE analysis and Western blot for identification of immunogens from filtrate proteins of A. fumigatus. (A) 2-DE of filtrate
proteins of A. fumigatus during growth in YEPG medum at 37°C for 14 days. (B) Immunoblot using pooled sera from proven IA patients. Filtrate
proteins (150 μg) were separated by isoelectric focusing on Immobiline Dry strips (pH range, 3-10) followed by SDS-PAGE and silver staining.
Standard molecular mass markers are indicated. Distinct protein spots (n = 39) with specific IgG immunoreactivity, as seen in corresponding
immunoblots (B), were subjected to tryptic digestion followed by MALDI-TOF-MS analysis for identification (marked with arrow). The 17 proteins
identified are numbered and listed in Table 2. Spot No. 2A-2 M was identified as thioredoxin reductase GliT.
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13 37 85 0.0015 5.95/46.9 Phenylalanine catabolism, Tyrosine catabolism
5 GI: 119492487 Neosartorya
fischeri NRRL 181







25 54 171 4.00E-12 6.30/61.4 Alcohol metabolism











19 62 137 9.90E-09 5.55/39.9 Glycolysis, Carbohydrate degradation




18 59 130 5.00E-08 6.06/35.3 Receptor signaling, intracellular signal transduction
pathways, and protein synthesis
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12 GI: 70988713 Aspergillus
fumigatus Af293
pectate lyase A 13 44 96 0.00014 6.23/33.8 Carbohydrate metabolism, cell wall biogenesis/
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fumigatus Af293
urate oxydase UaZ 12 32 80 0.0052 7.24/34.1 Metabolism of urate




23 70 258 7.90E-21 9.08/35.8 Cellular carbohydrate metabolic process
15 GI: 169764553 Aspergillus oryzae
RIB40







15 44 90 0.00052 6.33/36.0 Fatty acid metabolic process























an immunogen in patients with systemic candidiasis [32].
Furthermore, diverse groups have reported that some
metabolic enzymes interact specifically with human extra-
cellar matrix proteins, such as fibronectin, laminin, and
integrin-like vitronectin [33,34], and are involved in adhe-
sion and pathogenesis.
The immunodominant nature of these proteins is
valuable for the diagnosis of invasive fungal infections.
DppV, a member of the dipeptidyl-peptidase family in
A. fumigatus, is identical to one of the principal antigens
used in the diagnosis of IA. Moreover, DppV can gener-
ate protection responses, and improve the survival rate
of Aspergillus-infected mice [28]. DppV can also bind
with collagen or other human proteins and degrade
them, which can damage the host. Recombinant DppV
has shown a great potential in the serodiagnosis of IA in
immunocompromised and immunocompetent patients
[35]. NAD-dependent malate dehydrogenase, a key
enzyme in glycometabolism that catalyze the reversible
conversion between malate and oxaloacetate, was reported
recently as an allergen of A. fumigatus and A. versicolor
[29]. Malate dehydrogenase was also shown to be a Para-
coccidioides brasileinsis immunogenic protein [36] as well
as a Candida albicans immunogen [32]. Aspartyl amino-
peptidase, an enzyme that specifically degrades only
amino-terminal acidic amino acids from peptides, was
recently reported as an antigen of A. fumigatus [30].
TR of A. fumigatus has been described as an extracellu-
lar antigenic protein by two recent studies [30,31]. In one
former study, the secreted fraction of two geographically
different strains (190/96 and DAYA) of A. fumigatus were
used to identify new immunogenic molecules reacting
with pooled ABPA patient sera (IgG and IgE). TR was
only detected on 2DE immunoblots of the secreted
proteome of the DAYA strain probed with the IgE anti-
body fraction from pooled ABPA patients sera [31]. This
result suggested that TR might not be a good biomarker
for ABPA. In another study, the immunosecretome of
A. fumigatus was detected using pooled patient sera (total
n = 22 patients [ABPA, n = 11; aspergilloma, n = 5; IA,
n = 6]). The immunoreactive intensity of TR was lower
than most other proteins [30]. A possible explanation is
that the anti-TR antibody titers were not high in pooled
sera because most cases included in the study were not IA.
Although investigators in other laboratories recently
noted the antigenic nature of TR [30,31], no study has
found shown diagnostic value for TR in non-neutropenic
patients with IA. We showed that TR (spot no. 2A-2 M)
had the strongest immunoreactivity with patient sera. TR,
a component of the gliotoxin biosynthetic cluster, provides
self protection to A. fumigatus against gliotoxin [37,38].
This protein has been described as an extracellular protein
of A. fumigatus by Singh and Kumar [30,31]. However,
Schrettl et al. showed that GliT is preferentially localized
in the cytoplasm and nuclei by a GFP-GliT construct [38].
To predict whether or not GliT is actively secreted into
the culture supernatant, we used two bioinformatic tools
(SignalP and WoLF PSORT) to analyze its localization.
Our results support the findings of Singh and Kumar
[30,31]. Homology analysis indicated that TR had no
match with human proteins, as Kumar et al. [35] reported.
Muro et al. [39] also reported that the fungal TR has only
19% sequence similarity to human TR. Furthermore,
sequence homology analysis showed that TR of A. fumiga-
tus has low homology with most other Aspergillus species
as well as most other fungi. Therefore, TR could be con-
sidered as a specific antigen of A. fumigatus and as a
potential biomarker for the serological diagnosis of IA. In
Figure 3 SDS-PAGE and Western blot analysis of the recombinant thioredoxin reductase GliT (TR) of A. fumigatus. (A): SDS-PAGE
analysis of the recombinant TR expressed in Escherichia coli BL21. Lane M, molecular weight marker; lane 1, pET28a -TR in E. coli BL21, 1 mM
isopropyl-b- D - thiogalactoside induced for 5 h; lane 2, pET28a-TR in E. coli BL21, not induced; lane 3, purified recombinant TR; (B): Western blot
analysis of the purified recombinant TR with sera of 6 patients with proven IA, pooled control patients, and monoclonal mouse anti-His
antibody. lanes 1-6, Western blot of purified recombinant TR with sera from 6 patients with proven IA; lane 7, Western blot of purified
recombinant TR with sera of pooled control patients; lane 8, Western blot of purified recombinant TR with monoclonal mouse anti-His antibody.
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order to study its diagnostic potential, we cloned the TR
gene and purified the recombinant protein. Immunoblots
showed that recombinant protein could be recognized by
the sera from all six IA patients. These results suggested
that the TR of A. fumigatus could be developed as a bio-
marker for the diagnosis of IA, especially in critically ill
patients.
One of the strengths of our study was that all patients
included had histopathologic evidence and positive cul-
tures. This enabled us to discriminate between invasive
disease and colonization. However, we do realize that the
study design has limitations. We did not further investi-
gate the reactivity of individual patient serum with the
extracellular fraction of A. fumigatus, thus we cannot pro-
vide data whether or not these proteins consistently react
with individual IA patient serum. Moreover, the cases
used in this study were limited in number, therefore the
diagnostic value of the antigen identified should be vali-
dated in further prospective studies using large-scale
serum specimens.
Conclusions
Aspergillus fumigatus is known to be the most common
opportunistic pathogen that causes life-threatening IA in
humans. The ability of A. fumigatus to acquire and process
growth substrates from its host is dependent on the factors
the fungus releases. Studies on the extracellular proteins of
A. fumigatus and their immunogenic potential are there-
fore important for further understanding the pathogenesis
of A. fumigatus and targets for the immunodiagnosis of
the diseases. Our study has highlighted the immunodomi-
nant antigens of extracellular proteins. A total of 17 pro-
teins of A. fumigatus were identified as antigens in
humans. Some of the proteins have been reported as anti-
gens of Aspergillus and/or other fungi. Interestingly, our
study revealed the best immunoactive protein, TR, which
showed great potential for the diagnosis of IA.
Materials and methods
Patients and control subjects
Serum samples expressing high titers of antibodies against
the extracellular proteins of A. fumigatus were obtained
from six non-neutropenic-proven IA patients with differ-
ent underlying diseases. All serum samples were obtained
at the time of diagnosis. Two-to-four samples were
obtained sequentially per patient. Sera from 20 ICU
patients without clinical or microbiological evidence of IA,
including 8 patients with chronic obstructive pulmonary
disease, 6 patients with chronic renal disease, 3 patients
with renal transplantation, and 3 patients with acute pan-
creatitis (age range, 33-75 years), were used as negative
controls. Two samples were obtained per control patient
(one during early admission and one before leaving the
hospital). Aspergillus-specific IgG antibodies in the sera of
all patients were determined by an indirect ELISA using
filtrate proteins of A. fumigatus (1 μg/ml) as the coating
antigen (sera diluted 1:1000). All sera were stored at
-70°C. Sera of IA patients and controls were pooled sepa-
rately for immunoproteomics analysis. According to
EORTC-MSG criteria, proven IA refers to histopathologic
evidence of tissue invasion by septated, acutely-branching
filamentous fungi, together with a positive culture (sputum
and/or bronchoalveolar lavage) [39]. The study protocol
was approved by the Ethics Committee of the hospital and
informed consent was obtained from all patients included
in the study.
Preparation of extracellular proteins
A. fumigatus (strain CMCC (f) A1a) was obtained from the
Microbial Culture Collection Management Committee of
China, Medical Mycology Center. The fungus was first
grown on Sabouraud agar plates at 37°C for 3 days. The
conidia were collected and incubated in yeast-extract-pep-
tone-glucose (YEPG) broth (1% yeast extract, 2% peptone,
and 2% glucose) in a 500-ml flask on a shaker at 37°C for
14 days. Then, the culture supernatant was collected by fil-
tration. The proteins were recovered by trichloroacetic acid
(TCA) precipitation, as described previously [40]. Finally,
the precipitates were resuspended in two-dimensional elec-
trophoresis (2-DE; 7 M urea, 2 M thiourea, 4% [w/v]
CHAPS, 1% [w/v] DTT, 1% protease inhibitor cocktail [v/
v], and 2% [v/v] IPG buffer [pH 3-10]) lysis buffer, and
stored at -70°C. The protein concentration was determined
by the Bradford method using BSA as the standard.
Two-dimensional electrophoresis and Western blot
analysis
Samples containing 150 μg of filtrate protein were sepa-
rated by 2-DE, as described elsewhere [41], using immo-
bilized, non-linear pH 3-10 gradient strips (24 cm;
Amersham Biosciences, Uppsala, Sweden) for isoelectric
focusing, and 12.5% sodium dodecylsulfate polyacryla-
mide gels for the second dimension separation. All gels
were silver-stained according to published procedures
[42] or electrotransferred to polyvinylidene fluoride
(PVDF) membranes [43]. Three replicates were run for
each sample.
Western blot was performed as described previously
[44]. Briefly, the membranes were probed with primary
antibody (pooled sera of patients with proven IA and
pooled control sera [1:1000 dilution in each case]) at 4°C
overnight. Subsequently, the membranes were thrice
washed with Tris-buffered saline (pH 7.5) containing
0.05% (v/v) Tween-20 (TBST) for 10 min and incubated
with horseradish peroxidase (HRP)-conjugated goat anti-
human IgG (1:2000 dilution) for 2 h at room temperature.
The membranes were then washed with TBST and the
signal was detected with an enhanced chemiluminescence
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detection kit (Amersham Biosciences, Uppsala, Sweden).
The autoradiographs were developed using Kodak imaging
films according to the instrument of the manufactorer.
Three replicates were performed for each sample.
Protein identification and database searches
The specific immunoreactive protein spots were matched
through overlapping images of the blot and gel. The Wes-
tern blots were matched first with their own Ponceau
stain images, then were compared with the silver-stained
gel. Subsequently, the spots of interest were excised from
the 2DE gels for tryptic in-gel digestion and matrix-
assisted laser desorption ionization time-of-flight mass
spectrometry (MALDI-TOF-MS) on a time-of-flight Ultra-
flex II mass spectrometer (Bruker Daltonics, Bremen, Ger-
many). The peak lists of each protein spot were searched
against the NCBI database using Mascot (v2.1.03; Matrix
Sciences, London, UK). The following search parameter
criteria were used: significant protein MOWSE score at a
p < 0.05; minimum mass accuracy, 100 ppm; 1 missed
cleavage site allowed (cysteine carbamidomethylation,
acrylamide-modified cysteine, and methionine oxidation);
similarity of pI and relative molecular mass specified; and
minimum sequence coverage of 15%.
Bioinformatics analysis of TR
The signal peptide and the probability of TR were pre-
dicted using SignalP software (http://www.cbs.dtu.dk/ser-
vices/SignalP/). Another subcellular localization prediction
tool, WoLF PSORT (http://www.wolfpsort.org), was used
to analyze the amino acid sequences of proteins for pre-
diction of cellular localization. Homology analysis was per-
formed using the BLAST program (http://www.ncbi.nlm.
nih.gov/BLASTp and http://www.uniprot.org).
Expression, purification, and Western blot analysis of
recombinant thioredoxin reductase GliT
For RNA preparation, 100 mg of frozen mycelium was
ground under nitrogen and the whole RNA was extracted
using Trizol (Invitrogen, USA). cDNA was generated
using AMV reverse transcriptase (Promega, Madison, WI,
USA). The TR gene was amplified using the following pri-
mers: 5’-CACACATATGTCGATCGGCAAACTAC-3’
and 5’-ACTGAATTCCTATAGCTCCTGATCGAGACG-
3’. The resulting 1005-bp fragments were cloned into the
pET-28a (+) expression vector (Novagen, Germany). The
TR sequence was 100% identical to the gene of A. fumiga-
tus strain Af293. Then, the recombinant His6-TR was
expressed in E. coli BL21 competent cells, and purified
using a TALON metal affinity resin (Clontech, Japan).
Fractions containing the purified TR were pooled, dialyzed
against 0.1 M phosphate buffered saline (PBS; pH 7.2),
and stored at -70°C. Protein identity of the recombinant
TR was confirmed by MALDI-TOF MS.
Western blot of the purified recombinant proteins was
carried out as described earlier. Monoclonal mouse anti-
HIS antibody (diluted 1:4000), the serum samples from
six patients with proven IA, and pooled sera from
healthy individuals (diluted 1:1000) were used as pri-
mary antibodies. HRP-rabbit anti-mouse IgG (1:5000)
and HRP-goat anti-human IgG (diluted 1:2000) were
used as secondary antibodies. The antibody-bound pro-
teins were then visualized using the DAB kit (Maixin_-
Bio, China).
Additional material
Additional file 1: Histopathological results of 6 proven IA patients.
This figure shows the histopathological section of lung tissues obtained
from 6 proven IA patients exhibiting Aspergillus with septated and
acutely-branching hyphae.
Additional file 2: MS-based identification of all immunoreactive
protein of A. fumigatus during growth in YEPG medium at 37°C for
14 days. This table lists all MS-identified proteins that were marked in
Figure 2.
Additional file 3: BLAST search of A. fumigatus thioredoxin
reductase Glit in UniProtKB. This table lists 1000 BLAST results.
Additional file 4: MS spectra of the recombinant thioredoxin
reductase Glit. Protein identity of the recombinant thioredoxin
reductase Glit was confirmed by MALDI-ToF MS whereby peptides
(following tryptic digestion) were identified yielding 13 peptides
matched and 37% sequence coverage.
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